Top Markets
#1 Akedo Akedo +71.59%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.61%
#4 Cross Cross +34.10%
#5 Black Phoenix Black Phoenix +33.95%
#6 Cap Cap +29.61%
#7 Velvet Velvet +26.32%
#8 Ravencoin Ravencoin +17.91%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.35%
#10 DoubleZero DoubleZero +12.07%
Coin of the day
Akedo Akedo
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Hisse Senetlerindeki Sıralama #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Hisse Fiyatı
$0.073
Piyasa Değeri
$849.99K
Değişim (1 gün)
4.29%
Değişim (1 yıl)
21.67%
Ülke
US
Ticaret Hepion Pharmaceuticals, Inc. (HEPA)

Kategori

Healthcare
Hepion Pharmaceuticals, Inc. (HEPA) için gelir
Aug 2026 itibarıyla gelir TTM: 0
Hepion Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Hepion Pharmaceuticals, Inc. için 2026 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE